(Total Views: 365)
Posted On: 02/25/2021 11:23:26 AM
Post# of 149727
Here's the link:
https://us.gsk.com/en-us/media/press-releases...-covid-19/
It's interesting that other trials use the endpoint "alive and free of respiratory failure 28 days after treatment" rather than all-cause mortality at 28 days. I think the former will better flesh out meaningful results for those instances where the patient on placebo is alive after 28 days but they are just lingering in the ICU being kept alive by the ventilator or ECMO.
https://us.gsk.com/en-us/media/press-releases...-covid-19/
It's interesting that other trials use the endpoint "alive and free of respiratory failure 28 days after treatment" rather than all-cause mortality at 28 days. I think the former will better flesh out meaningful results for those instances where the patient on placebo is alive after 28 days but they are just lingering in the ICU being kept alive by the ventilator or ECMO.
(2)
(0)Scroll down for more posts ▼
